"It ain't bragging if you can back it up." Jay "Dizzy" Dean- St. Louis Cardinals, 1934CytoDyn is backing up what leronlimab can do. The game will heat up when the data is firmed up.
Big Pharma is looking at Pfizer's $43 Billion buyout of Seagen and its phase 3 failure (SigVie-002 study) along with Pfizers $5.4 Billion acquisition of Global Blood Theraputics and its phase 3 failure of inclacumab last year. A lot of Big Pharma caution is out there currently.
A point will be reached soon as the data from these active leronlimab studies become known so that Big Pharma will decide the risk/reward factor is favorable and we will then see some pretty exciting action. You ever notice how quiet it gets before a big storm comes through?
So CytoDyn won't ever brag. It'll publish factual data about a real drug that will change medicine in a big way. This low key but steady approach is being followed closely by several high key pharmaceutical companies. FDA appreciates the no-brag all data approach also.
The stock price is being so manipulated currently that it is almost laughable, unless you realize what is happening and add to your cache.
This is a very exciting time and I'm very happy to be involved in this endeavor. I'm pretty sure my family members will be happy also along with a large number of people with disease processes that utilize CCR5 in the disease process.
Big Pharma is looking at Pfizer's $43 Billion buyout of Seagen and its phase 3 failure (SigVie-002 study) along with Pfizers $5.4 Billion acquisition of Global Blood Theraputics and its phase 3 failure of inclacumab last year. A lot of Big Pharma caution is out there currently.
A point will be reached soon as the data from these active leronlimab studies become known so that Big Pharma will decide the risk/reward factor is favorable and we will then see some pretty exciting action. You ever notice how quiet it gets before a big storm comes through?
So CytoDyn won't ever brag. It'll publish factual data about a real drug that will change medicine in a big way. This low key but steady approach is being followed closely by several high key pharmaceutical companies. FDA appreciates the no-brag all data approach also.
The stock price is being so manipulated currently that it is almost laughable, unless you realize what is happening and add to your cache.
This is a very exciting time and I'm very happy to be involved in this endeavor. I'm pretty sure my family members will be happy also along with a large number of people with disease processes that utilize CCR5 in the disease process.
24
